Vir Biotechnology (VIR) Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VIR shares.
View VIR analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued 12-month price targets for Vir Biotechnology's shares. Their VIR share price forecasts range from $14.00 to $95.00. On average, they expect the company's share price to reach $37.11 in the next twelve months. This suggests a possible upside of 305.1% from the stock's current price.
View analysts price targets for VIR or view top-rated stocks among Wall Street analysts.

Vir Biotechnology's stock was trading at $25.31 at the beginning of the year. Since then, VIR stock has decreased by 63.8% and is now trading at $9.16.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our VIR earnings forecast.

Vir Biotechnology, Inc. (NASDAQ:VIR) issued its earnings results on Thursday, August, 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.21) by $0.24. The company had revenue of $3.80 million for the quarter, compared to the consensus estimate of $22.39 million. Vir Biotechnology had a negative net margin of 53.38% and a negative trailing twelve-month return on equity of 13.08%. The business's revenue was up 379999900.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.58) EPS.

ETFs with the largest weight of Vir Biotechnology (NASDAQ:VIR) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Hartford Multifactor Small Cap ETF (ROSC) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).SPDR S&P 600 Small Cap ETF (SLY).

7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees.

(VIR) raised $149 million in an initial public offering on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO.

Vir Biotechnology trades on the NASDAQ under the ticker symbol "VIR."

Vir Biotechnology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (23.88%), SB Investment Advisers UK Ltd. (12.43%), BlackRock Inc. (10.41%), State Street Corp (4.04%), Temasek Holdings Private Ltd (3.82%) and Baillie Gifford & Co. (2.97%). Insiders that own company stock include Ann M Hanly, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Jay Parrish, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Vicki L Sato and Vicki L Sato.
View institutional ownership trends.

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VIR stock can currently be purchased for approximately $9.16.

Vir Biotechnology (NASDAQ:VIR) has a market capitalization of $1.23 billion and generates $1.62 billion in revenue each year. The company earns $515.84 million in net income (profit) each year or ($1.97) on an earnings per share basis.

The company employs 576 workers across the globe.

Vir Biotechnology's mailing address is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. The official website for the company is www.vir.bio. The company can be reached via phone at 415-906-4324 or via email at ir@vir.bio.